Key Highlights

  • 26.7 million USD is the cash and equivalents balance NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) held at June 30, 2026, up from USD 7.8 million at December 31, 2025, mainly after a public offering.
  • 18.0 million USD is the net loss of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) for the six months ended June 30, 2026, versus USD 23.1 million a year earlier, while the net operating loss rose to USD 11.3 million.
  • 22.3 million USD is the gross proceeds of the Equity offering completed by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), including full exercise of the underwriters' option, which funded the rise in its cash balance.
  • 11.5 million USD is the anticipated non-dilutive DARPA funding for the SPARC-TMS trial in which NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was selected as prime contractor, subject to completion of contracting.

What Investors Expect From NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) on November 16, 2026

NRx Pharmaceuticals is scheduled to report third quarter 2026 results on Monday, November 16, 2026, for the quarter ended September 30, 2026. The prior report, released on August 17, 2026 with a call at 4:30 p.m. ET, showed a six-month net loss of USD 18.0 million and net operating loss of USD 11.3 million, compared with USD 7.6 million in 2025. Investors will watch spending on commercial launch preparation, clinic activity and progress toward the first commercial sales of ketamine targeted for 2026.

The Rationale: Last Reported Quarter and Management Outlook for NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

The first-cycle FDA review of the preservative-free ketamine abbreviated new drug application is complete with no drug-related major deficiencies. One deficiency concerned the vial luer lock component, and the manufacturer has submitted its attestation. The company targets approval and commercialization in 2026, with 5 million units of launch stock in Manufacturing and planned output of 1 million units per month. For NRX-100, the company relies on real-world evidence from more than 65,000 patients and aims for approval in 2027. Chief Executive Officer Jonathan Javitt called the second quarter a major inflection point.

Valuation, Liquidity and Risks for NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Management expects existing cash, clinic Revenue growth and use of its at-the-market offering to support operations for at least one year. The increase in operating loss reflects Research and Development costs for acquired Assets and higher selling, general and administrative expense, including new key personnel and launch costs. Risks include FDA approval timing, remaining manufacturing items, dependence on real-world evidence, commercial execution, equity dilution from offerings, and the completion of DARPA contracting before the anticipated funding of USD 11.5 million is realized.

Where Things Stand

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) reports on November 16, 2026 as it transitions from a clinical-stage developer toward a commercial company. Cash of USD 26.7 million and a six-month net loss of USD 18.0 million frame the financial position, while the net operating loss of USD 11.3 million shows rising launch and personnel costs. The ketamine abbreviated application, targeted for approval in 2026, is the nearest catalyst, followed by the NRX-100 application aimed at 2027 and the NRX-101 Phase 2 and 3 trial with DARPA support. The third quarter release should update regulatory timing, spending and the length of the funded runway.